Claims for Patent: 10,184,010

Summary for Patent: 10,184,010

Title:	Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
Abstract:	The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (DLL4); and an antibody that binds specifically to vascular endothelial cell growth factor (VEGF).
Inventor(s):	Lee; Dong Heon (Daejeon, KR), Moon; Kyung Duk (Daejeon, KR), Choi; Yu Bin (Daejeon, KR), Kang; Kyung Jae (Daejeon, KR), Kim; Dong In (Daejeon, KR), Ahn; Jin Hyung (Daejeon, KR), You; Weon Kyoo (Daejeon, KR), Jung; JinWon (Daejeon, KR)
Assignee:	ABLBIO (Seoul, KR)
Application Number:	14/903,077
Patent Claims:	1. A dual-targeting protein comprising: a protein specifically binding to DLL4, which recognizes a conformational epitope of DLL4 comprising amino acid residues 58-65 and 110-115 of SEQ ID NO:21, and an antibody specifically binding to VEGF(Vascular endothelial growth factor), wherein the protein specifically binding to DLL4 comprises: a heavy chain variable region comprising heavy chain CDR1 having the amino acid sequence of SEQ ID NO:2, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:3, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:4, and a light chain variable region comprising light chain CDR1 having the amino acid sequence of SEQ ID NO:5, light chain CDR2 having the amino acid sequence of SEQ ID NO:6, and light chain CDR3 having the amino acid sequence of SEQ ID NO:7. 2. The dual-targeting protein of claim 1, wherein the dual-targeting protein is a form in which the protein that binds specifically to DLL4 and an IgG (immunoglobulin G)-type antibody that binds specifically to VEGF are connected to each other by a linker. 3. The dual targeting protein of claim 2, wherein the linker is a peptidyl linker or a non-peptide linker. 4. The dual targeting protein of claim 3, wherein the peptide linker has an amino acid sequence of SEQ ID NO:18. 5. The dual-targeting protein of claim 1, wherein the protein binding specifically to DLL4 comprise the heavy-chain amino acid sequence of SEQ ID NO: 8 and the light-chain amino acid sequence of SEQ ID NO: 9. 6. The dual targeting protein of claim 1, wherein the antibody specifically binding to VEGF comprising: a heavy chain variable region comprising heavy chain CDR1 having the amino acid sequence of SEQ ID NO:10, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:11, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:12, and a light chain variable region comprising light chain CDR1 having the amino acid sequence of SEQ ID NO:13, light chain CDR2 having the amino acid sequence of SEQ ID NO:14, and light chain CDR3 having the amino acid sequence of SEQ ID NO:15. 7. The dual targeting protein of claim 1, wherein the antibody specifically binding to VEGF comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:16 and a light chain variable region having the amino acid sequence of SEQ ID NO:17. 8. The dual-targeting protein of claim 7, wherein the antibody binding specifically to VEGF is Bevacizumab. 9. The dual-targeting protein of claim 1, wherein the dual-targeting protein comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:1 and a light chain variable region having the amino acid sequence of SEQ ID NO:20. 10. The dual targeting protein of claim 1, wherein the protein binding specifically to DLL4 is in the form of full-length antibodies, Fab', F(ab')2, Fab, Fv, rIgG, or scFv(Single-chain variable fragment). 11. A polynucleotide encoding the dual-targeting protein of claim 1. 12. An expression vector comprising the polynucleotide of claim 11. 13. A transformant introduced with the expression vector of claim 12. 14. A method for producing a dual-targeting protein comprising a protein that binds specifically to DLL4 and an antibody that binds specifically to VEGF (vascular endothelial growth factor), the method comprising the steps of: (a) culturing the transformant according to claim 13 to produce a dual-targeting protein; and (b) recovering the dual-targeting protein produced in step (a).

Details for Patent 10,184,010

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-07-09
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	12/12/2018		2033-07-09